Researchers reveal mechanisms of how CDK12 alterations drive prostate cancer development

When researchers at the University of Michigan Rogel Cancer Center first identified a new subtype of aggressive prostate cancer, they knew they needed to understand how this genetic alteration was driving cancer and how to target it with treatment.

GoodRx Offers 30 Meds Under $30 for Heart Conditions

What You Should Know: GoodRx, a prescription savings platform, is stepping up to help with a new program offering 30 common heart health medications for

February 16, 2024

New Zealand clears first clinical trial of epigenetic editing for hepatitis B

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 15, 2024

Pharmalittle: We’re reading about FTC reviewing Novo-Catalent deal, Amneal opioid settlement, and more

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and inspiring, because that oh-too predictable routine of online

May 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.